Introduction – Company Background

GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.

With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.

With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.

From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.

At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.

By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.

Core Strengths in Insole Manufacturing

At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.

Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.

We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.

With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.

Customization & OEM/ODM Flexibility

GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.

Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.

With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.

Quality Assurance & Certifications

Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.

We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.

Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.

ESG-Oriented Sustainable Production

At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.

To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.

We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.

Let’s Build Your Next Insole Success Together

Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.

From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.

Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.

🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw

Pillow ODM design company in Taiwan

Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.

With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.China custom insole OEM supplier

Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.

We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.ODM pillow factory in Vietnam

At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Innovative insole ODM solutions in Vietnam

📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Thailand eco-friendly graphene material processing

Researchers are investigating bacteriophages, particularly “jumbo” phages with large genomes, as potential tools to combat antibiotic-resistant bacteria. These phages might be engineered to deliver antibiotics directly to infections, offering a new strategy in the fight against deadly pathogens. In the early 20th century, antibiotics gained widespread recognition as an effective treatment for bacterial infections. In what is deemed as the antibiotic golden age, they were regularly developed throughout the mid-20th century. However, this golden age did not last. As antibiotics were prescribed more frequently, bacteria evolved. They became better equipped to defeat antibiotics, rendering many useless. The sharp downturn in the effectiveness of antibiotics continued and has resulted in today’s antibiotic resistance crisis. Therapeutic Potential of Jumbo Phages Scientists now look to an unusual ally, viruses, to help counter this rising threat. Recently, researchers have focused on viruses known as bacteriophages as a new tool to treat and disarm antibiotic-resistant bacteria. Special attention has been placed on “jumbo” phages — viruses recently discovered to feature extremely large genomes — that could be tapped as special delivery agents that can not only kill bacteria but could be engineered to deliver antibiotics directly to the source of infection. But in order to deliver novel therapeutics through phage, scientists must first understand the extraordinary biological makeup and mechanisms inside these mysterious viruses. A graphic image of PicA, a key component of jumbo phage that coordinates protein trafficking across the protective shell of the phage nucleus. Credit: Pogliano Labs, UC San Diego Research and Findings University of California San Diego School of Biological Sciences researchers and their colleagues at UC Berkeley’s Innovative Genomics Institute and the Chulalongkorn University in Bangkok have taken a substantial step forward in deciphering several key functions within jumbo phages. “These jumbo phages have large genomes that in theory could be manipulated to carry payloads that more effectively kill bacteria,” said Joe Pogliano, a UC San Diego professor in the School of Biological Sciences and senior author of the new paper, which was published recently in the Proceedings of the National Academy of Sciences. “The problem is that their genome is enclosed so it’s not easy to access. But now we’ve discovered some of its key elements.” As described in the paper, research led by School of Biological Sciences graduate student Chase Morgan focused on jumbo Chimalliviridae phages that were found to replicate inside bacteria by forming a compartment that resembles the nucleus inside the cells of humans and other living organisms. The Chimalliviridae’s nucleus-like compartment separates and selectively imports certain proteins that allow it to replicate inside the host bacteria. But how this process unfolds had been a puzzling part of the process. The jumbo virus phikzvirus, or phiKZ, is known to infect Pseudomonas bacteria. Credit: Pogliano Labs, UC San Diego Using new genetic and cell biology tools, Morgan and his colleagues identified a key protein, which they named “protein importer of Chimalliviruses A,” or PicA, that acts as a type of nightclub bouncer, selectively trafficking proteins by granting entry inside the nucleus for some but denying access for others. PicA, they found, coordinates cargo protein trafficking across the protective shell of the phage nucleus. “Just the fact that this virus is able to set up this incredibly complex structure and transport system is really amazing and the likes of which we haven’t seen before,” said Morgan. “What we think of as complex biology is usually reserved for higher life forms with humans and our tens of thousands of genes, but here we are seeing functionally analogous processes in a comparatively tiny viral genome of only approximately 300 genes. It’s probably the simplest selective transport system that we know of.” Using CRISPRi-ART, a programmable RNA tool for studying genomes, the researchers were able to demonstrate that PicA is an essential component of the Chimalliviridae nucleus development and replication process. “Without the simplicity and versatility of RNA-targeting CRISPR technologies, directly asking and answering these questions would be nearly impossible. We are really excited to see how these tools unravel the mysteries encoded by phage genomes,” said co-author Ben Adler, a postdoctoral scholar working under Nobel Prize-winning CRISPR pioneer Jennifer Doudna. School of Biological Sciences graduate students Chase Morgan and Emily Armbruster, coauthors of the PNAS paper. Credit: Pogliano Labs, UC San Diego Implications for Phage Therapy Bacteria and viruses have engaged in a type of arms race for billions of years, each evolving to counter the other’s adaptations. The researchers say the sophisticated PicA transportation system is a result of that intense, ongoing evolutionary competition. The system has evolved to be both highly flexible and highly selective, allowing only key beneficial elements inside the nucleus. Without the PicA system, the bacteria’s defensive proteins would work their way inside and sabotage the virus’ replication process. Such information is vital as scientists with the Howard Hughes Medical Institute (HHMI)-funded Emerging Pathogens Initiative and UC San Diego’s Center for Innovative Phage Applications and Therapeutics strive to lay the groundwork to eventually genetically program phage to treat a variety of deadly diseases. “We really didn’t have any understanding of how the protein import system worked or which proteins were involved previously, so this research is the first step in understanding a key process that’s critical for these phage to successfully replicate,” said School of Biological Sciences graduate student Emily Armbruster, a paper coauthor. “The more we understand these essential systems, the better we will be able to engineer phage for therapeutic use. Future targets for such genetically programmed viruses include Pseudomonas aeruginosa bacteria, which are known to cause potentially fatal infections and pose risks for patients in hospitals. Other promising targets include E. coli and Klebsiella which can cause chronic and recurrent infections and, in some cases, enter the bloodstream which can be life-threatening. Reference: “An essential and highly selective protein import pathway encoded by nucleus-forming phage” by Chase J. Morgan, Eray Enustun, Emily G. Armbruster, Erica A. Birkholz, Amy Prichard, Taylor Forman, Ann Aindow, Wichanan Wannasrichan, Sela Peters, Koe Inlow, Isabelle L. Shepherd, Alma Razavilar, Vorrapon Chaikeeratisak, Benjamin A. Adler, Brady F. Cress, Jennifer A. Doudna, Kit Pogliano, Elizabeth Villa, Kevin D. Corbett and Joe Pogliano, 30 April 2024, Proceedings of the National Academy of Sciences. DOI: 10.1073/pnas.2321190121

Scientists identified a link between the ion transport protein ZIP7 and the cell’s protein degradation system, the proteasome. This discovery provides a promising avenue for treating diseases caused by protein misfolding, such as Alzheimer’s and Parkinson’s. Researchers have identified a gene therapy target that could potentially slow the development and progression of degenerative diseases. Proteins serve as building blocks, receptors, processors, couriers, and catalysts in organisms. A protein’s structure is critical to its function. Misfolded proteins are unable to carry out their tasks and can also accumulate, leading to a variety of incurable degenerate diseases such as Alzheimer’s, Parkinson’s, and retinitis pigmentosa. In a new paper published by Developmental Cell, researchers from the University of California, Santa Barbara reveal a new connection between the ion transport protein ZIP7 and the cell’s proteasome, which degrades misfolded proteins. This link offers a promising target for treating a variety of degenerative diseases caused by protein misfolding. This is a story about proteins, how they malfunction, and what cells do to prevent that. Credit: Matt Perko, UC Santa Barbara ZIP7 and Cellular Mobility For 35 years, Montell’s lab has studied the movement of cells in fruit fly ovaries. “By studying basic cell biology in fruit fly ovaries, we stumbled upon a way to prevent neurodegeneration, and we think this has potential applications in the treatment of some human diseases,” said senior author Denise Montell, Duggan Professor and Distinguished Professor in the Department of Molecular, Cellular, and Developmental Biology. “Cell movement underlies embryonic development, drives wound healing and contributes to tumor metastasis,” she explained. “So it’s a really fundamental cell behavior that we care to understand deeply.” In previous work, Monell’s team discovered a mutation in a gene called ZIP7, which encodes a protein of the same name, that impaired cell mobility. The ZIP7 protein ferries zinc ions within a cell. These ions are exceedingly rare within the cytoplasm but abundant in proteins where they often form part of the architecture and catalyze chemical reactions. “ZIP7 is conserved in evolution from plants to yeast to flies to humans,” Montell said. “So it’s doing something really fundamental, because it’s been around for a really long time.” Proteasomes grind up misfolded proteins tagged for recycling, but the enzyme Rpn11 must first remove that tag so the protein can fit. Credit: Xiaoran Guo and Morgan Mutch et al. ZIP7 is also the only zinc transporter found in the endoplasmic reticulum, a membranous structure where a cell makes proteins destined for the outer membrane of the cell or for secretion out of the cell. About a third of our proteins are made here. If ZIP7 is our protagonist, then misfolded proteins and their disposal are the theme of the study. For proteins, function follows form. It’s not enough to have the right ingredients, a protein must fold correctly to function properly. Misfolded proteins are responsible for a host of diseases and disorders. But proteins will sometimes misfold even in a healthy cell. Fortunately, cells have a quality control system to deal with this eventuality. If the error is small, the cell can try folding it again. Otherwise, it will tag the misfolded molecule with a small protein called ubiquitin and send it out of the endoplasmic reticulum (ER) for recycling. Waiting in the cytoplasm are structures called proteasomes, the “garbage disposals” of the cell. “It literally chews up the protein into little pieces that can then be recycled,” Montell said. “But if the garbage disposal gets overwhelmed — somebody puts too many potato peels in there — then the cell experiences ER stress.” This triggers a response that slows down protein synthesis (pauses our potato prep) and produces more proteasomes so that the system can clear the backlog of waste. If all this fails, the cell undergoes programmed death. Study Details and Findings Co-lead author Xiaoran Guo, Montell’s former Ph.D. student, saw that loss of ZIP7 caused ER stress in the fruit fly’s ovary. So she set out to determine if this stress was the reason the cells lost their mobility. Indeed, inducing ER stress with a different misfolded protein also impaired cell migration. When Guo over-expressed ZIP7 in these cells, the backlog of misfolded proteins disappeared, the ER stress vanished, and the cells regained their mobility. “I was so surprised that I had to question myself if I had done everything correctly,” Guo said. “If this was real, just ZIP7 alone must be very potent in resolving ER stress.” What’s more, the misfolded protein she used, called rhodopsin, contains no zinc in its structure. This led Guo to suspect that ZIP7 must be involved somewhere in the degradation pathway. Co-lead author, and fellow doctoral student, Morgan Mutch used a drug to block the proteasome from degrading misfolded rhodopsin and observed that this negated the beneficial effect of ZIP7. She concluded that ZIP7 must be acting somewhere before the proteasome munches up the misfolded protein. The authors created four modified ZIP7 genes: two mutations disrupted the protein’s ability to carry zinc, while the other two left this unchanged. They discovered that zinc transport was critical in reducing ER stress. At this point, a new character enters our story: the enzyme Rpn11, which forms part of the proteasome. Much like trying to stuff a large head of broccoli down the disposal, misfolded proteins with ubiquitin tags don’t fit into the proteasome. Rpn11 snips off these tags, enabling the misfolded protein to slip into the proteasome core for disassembly. Zinc is essential for Rpn11 to catalyze the removal of ubiquitin. “I was very surprised, and then excited, when I saw that increasing ZIP7 expression almost completely prevented the buildup of those ubiquitin-tagged proteins,” Mutch said. “We were expecting the opposite result.” Mutch determined that ZIP7 was critical in supplying zinc to Rpn11, enabling it to trim the tags that label defective proteins so that they fit into the structure that actually breaks them down. Blocking the Rpn11 enzyme confirmed this hypothesis. “That feeling when you discover something new, something no one has figured out before, is the best feeling for a scientist,” Mutch added. Therapeutic Implications The results suggest that overexpressing ZIP7 could form the basis for treating a variety of diseases. For instance, misfolded rhodopsin causes retinitis pigmentosa, a congenital blinding disease that is currently untreatable. Scientists already have a strain of fruit flies with the mutation that causes a similar disease, so the team overexpressed the ZIP7 gene in these flies to see what would happen. “We found that it prevents retinal degeneration and blindness,” Montell said. Every single one of the flies with mutant rhodopsin usually develops retinitis pigmentosa, but a full 65% of those with overactive ZIP7 formed eyes that respond normally to light. Montell’s lab is now collaborating with Professor Dennis Clegg, also at UC Santa Barbara, to further investigate the effect of ZIP7 in human retinal organoids, tissue cultures that bear a mutation that causes retinitis pigmentosa. This project was originally funded by the National Institute for General Medical Sciences. For the next three years, it will be supported by a $900,000 grant from the Foundation Fighting Blindness so Montell, Clegg, and their colleagues can test the hypothesis that ZIP7 gene therapy will prevent blindness in retinitis pigmentosa patients. What’s more, proteasome capacity declines as we get older, contributing to many classic signs of aging and increasing the probability of age-related degenerative diseases. Therapies targeting ZIP7 could potentially slow the development or progression of these ailments, as well. They’ve already yielded promising results extending fruit fly lifespan. “This is a poster child for fundamental, curiosity-driven research,” Montell said. “You’re just studying something because it’s cool, and you follow the data and end up discovering something you never set out to study, possibly even a cure for multiple diseases.” Reference: “The Zn2+ transporter ZIP7 enhances endoplasmic-reticulum-associated protein degradation and prevents neurodegeneration in Drosophila” by Xiaoran Guo, Morgan Mutch, Alba Yurani Torres, Maddalena Nano, Nishi Rauth, Jacob Harwood, Drew McDonald, Zijing Chen, Craig Montell, Wei Dai and Denise J. Montell, 25 April 2024, Developmental Cell. DOI: 10.1016/j.devcel.2024.04.003

Researchers in Brazil identified probiotic Lactobacillus strains in traditional cheeses, finding them safe and beneficial. The strains could enhance cheese quality without altering its composition, though more research is needed to confirm their industrial viability. In a new paper, researchers from Brazil discuss the benefits of three Lactobacillus bacteria strains for human health and their applications in the cheese industry. Research conducted at the Center for Dairy Technology (Tecnolat) in Campinas, São Paulo state, Brazil, has identified lactic acid bacteria (LAB) that have probiotic properties and are beneficial to human health in samples of traditional Brazilian cheeses. Tecnolat is part of the Food Technology Institute (ITAL), an arm of the São Paulo State Department of Agriculture and Supply. The researchers analyzed three strains of bacteria belonging to the genus Lactobacillus from Tecnolat’s bacterial strain bank. The bacteria were isolated from traditional Brazilian cheeses, such as Prato and Minas, for example. These and other LAB are recognized for their probiotic potential and are widely used by the food industry in products such as yogurt, kombucha, and kefir, as well as cheese. “We selected these strains after screening the entire strain bank to see which isolates had been found to have the best fermentative, enzymatic, and sensory properties in previous research conducted at Tecnolat,” said Cristian Mauricio Barreto Pinilla, first author of the article and a researcher at ITAL with a PhD in food science and technology. Samples of Prato cheese produced with the three strains of Lactobacillus studied at ITAL. Credit: Cristian Mauricio Barreto and Leila Spadoti/ITAL Genome Sequencing and Functional Testing The next step was to obtain the complete genomes of the isolates so as to identify them correctly and evaluate their functional properties and safety. This was followed by in vitro tests to confirm that the bacteria were safe and probiotic. “We analyzed this information, focusing on the technological properties of the isolates, with a view to producing pilot batches of Prato cheese containing each of the three strains. We also studied the changes in physicochemical parameters, bacterial communities, volatile compounds [responsible for aroma and flavor], and fatty acids during cheese ripening,” Barreto explained. The study was supported by FAPESP and reported in an article published in the journal Current Microbiology. The findings show that all three Lactobacillus isolates are safe for consumption, have potential as novel probiotics, and have strong inhibitory effects against some of the pathogens that may be present in dairy produce. Furthermore, none of the three strains significantly affected the physicochemical composition of the cheese containing them in terms of fatty acid and protein profiles. “We also observed a drop in levels of undesirable volatile compounds during longer maturation periods for cheeses containing the cultures, but each strain produced a different profile in this regard,” Barreto said, explaining that this is important for diversification, quality, and shelf life of cheeses with a maturation period of more than 25 days. “We need to find out more about certain aspects, such as a possible reduction in deteriorating and pathogenic microorganisms in cheese due to the action of our Lactobacillus strains.” Industrial and Market Potential The conclusions met the aim of the study, he said, which was to analyze Lactobacillus strains derived from Brazilian biodiversity with probiotic and technological properties suitable for use in cheese production so as to enhance the sensory diversity and microbiological quality of the products, while also benefiting the health of consumers. “This kind of microorganism is easy to produce industrially, favoring studies designed to optimize the use of low-cost nutrients such as serum. Research along these lines is relevant to the needs of the cheese industry, which has significant growth potential but is cramped by the limited market for probiotics, dominated by large multinational companies,” he said. Although microbial culture technology is well-established in the multinationals that supply cultures to Brazil, it is necessary to develop local companies with the capacity to produce cultures for traditional Brazilian products that are competitive and meet the needs of small and medium producers for high-quality products with enhanced sensory properties, he added. The studies conducted by the team to date have had good results, but more research is needed for the industry to be able to use these strains and to ensure their classification as probiotics. “We need to conduct tests in an animal model, followed by clinical trials that enable us to comply with the regulatory requirements. These procedures take time and are costly,” Barreto said. Reference: “Probiotic Potential and Application of Indigenous Non-Starter Lactic Acid Bacteria in Ripened Short-Aged Cheese” by Cristian Mauricio Barreto Pinilla, Adriano Brandelli, Henrique Ataíde Isaia, Frank Guzman, Marco Antônio Sundfeld da Gama, Leila Maria Spadoti and Adriana Torres Silva e Alves, 3 June 2024, Current Microbiology. DOI: 10.1007/s00284-024-03729-2

DVDV1551RTWW78V